SNDL Past Earnings Performance
Past criteria checks 0/6
SNDL's earnings have been declining at an average annual rate of -16.8%, while the Pharmaceuticals industry saw earnings declining at 0.8% annually. Revenues have been growing at an average rate of 69.8% per year.
Key information
-16.8%
Earnings growth rate
51.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 69.8% |
| Return on equity | -14.0% |
| Net Margin | -18.5% |
| Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
SNDL Inc. (NASDAQ:SNDL) Shares Fly 60% But Investors Aren't Buying For Growth
Mar 28
SNDL Inc.'s (NASDAQ:SNDL) Revenues Are Not Doing Enough For Some Investors
Jan 15SNDL Inc.'s (NASDAQ:SNDL) 25% Dip In Price Shows Sentiment Is Matching Earnings
Jun 22Are Investors Undervaluing SNDL Inc. (NASDAQ:SNDL) By 22%?
Dec 12SNDL Starting To Stand Out Among Canadian Cannabis Players
Aug 05Sundial Growers whipsaws ahead of shareholder meeting on reverse stock split
Jul 20Sundial Growers Looking Bullish As Revenue Growth From Acquisitions Increases
May 19Sundial Growers Doubles Revenue With Spiritleaf Acquisition And Reports Positive EBITDA For Q4-2021
Apr 28Sundial Growers' Cash War Chest And Its Bid To Avoid Another Dilution
Mar 21Sundial Growers Stock: What To Watch For Going Into 2022
Dec 28Taking A Look At The Canadian Cannabis Penny Stock: Sundial Growers
Nov 04Sundial Moves On Alcanna Acquisition And Nova Cannabis Investment
Oct 12Sundial: A Speculative Buy On The Restructure
Sep 25Insight Into Sundial Growers' Q2 2021 Earnings Report
Aug 24Sundial: Can The Recent Acquisition Turn This Story Around?
Jul 23Evaluating Sundial Growers' Acquisition Of Inner Spirit And Partnership With SAF Group
Jul 01Sundial Growers regains Nasdaq compliance
Jun 16Sundial Growers: Finding Ways To Spend That $1.1B Cash
Jun 01Sundial Growers boosts stake in The Valens Company
May 04Sundial Growers: The Luckiest Cannabis Stock Of 2021
Feb 04Cannabis producer Sundial up more than 17% following 14% loss prior day
Feb 03Sundial Growers trades in red on pricing $74.5M offering
Feb 02Sundial Growers raises $100M capital through registered offering
Jan 29Sundial launched premium concentrates products under Top Leaf brand
Jan 12Sundial Growers: A Busy End To 2020 Indicates Potential Strategic Expansion
Jan 11After another catalyst, Motley Fool sizes up cannabis sector
Jan 08Sundial, HEXO lead out big gains in cannabis sector
Jan 06Seeking Alpha Catalyst Watch
Dec 31Sundial acquires C$59M special purpose vehicle
Dec 30Sundial cheers concentrates license agreement with Simply Solventless
Dec 28Sundial prepays C$50M of senior secured non-revolving term credit facility
Dec 15Sundial Growers: Not Out Of The Weeds Yet
Nov 23Sundial Growers Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 12Sundial Growers misses on revenue
Nov 11Revenue & Expenses BreakdownBeta
How SNDL makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 909 | -168 | 230 | 0 |
| 30 Sep 23 | 901 | -211 | 221 | 1 |
| 30 Jun 23 | 894 | -287 | 213 | 2 |
| 31 Mar 23 | 897 | -331 | 196 | 2 |
| 31 Dec 22 | 712 | -335 | 158 | 2 |
| 30 Sep 22 | 495 | -266 | 124 | 3 |
| 30 Jun 22 | 278 | -151 | 88 | 2 |
| 31 Mar 22 | 64 | -130 | 60 | 2 |
| 31 Dec 21 | 56 | -227 | 55 | 2 |
| 30 Sep 21 | 47 | -228 | 50 | 2 |
| 30 Jun 21 | 46 | -316 | 49 | 1 |
| 31 Mar 21 | 57 | -296 | 45 | 0 |
| 31 Dec 20 | 61 | -200 | 46 | 0 |
| 30 Sep 20 | 62 | -170 | 59 | 1 |
| 30 Jun 20 | 77 | -184 | 70 | 1 |
| 31 Mar 20 | 76 | -164 | 80 | 3 |
| 31 Dec 19 | 64 | -143 | 86 | 2 |
| 30 Sep 19 | 49 | -156 | 72 | 2 |
| 30 Jun 19 | 21 | -84 | 54 | 2 |
| 31 Mar 19 | 1 | -77 | 37 | 0 |
| 31 Dec 18 | 0 | -68 | 22 | 0 |
| 28 Feb 18 | 0 | -13 | 9 | 0 |
Quality Earnings: SNDL is currently unprofitable.
Growing Profit Margin: SNDL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SNDL is unprofitable, and losses have increased over the past 5 years at a rate of 16.8% per year.
Accelerating Growth: Unable to compare SNDL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SNDL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.7%).
Return on Equity
High ROE: SNDL has a negative Return on Equity (-13.99%), as it is currently unprofitable.